{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:35:53Z","timestamp":1791588953185,"version":"4.3.4"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Psoriasis is a chronic inflammatory skin disease linked to immune system. Despite its prevalence, the precise aetiology and pathogenesis of psoriasis remain elusive. This study aimed to assess the efficacy and safety of Secukinumab while exploring its impact on the intestinal microbiota in patients with moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>We recruited 60 healthy controls and 110 patients with moderate-to-severe plaque psoriasis who attended outpatient clinics between June 2022 and June 2023. Clinical data (gender, age, BMI, PASI score, PGA, DLQI, Itch NRS, and STAI score) and faecal samples were collected from all groups. Faecal samples underwent PacBio Full-Length Diversity Sequencing and subsequent informatics analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Patients were randomly assigned to two groups: Before Secukinumab treatment group (BT, n = 55), After 24 weeks of Secukinumab treatment group (AT, n = 55). Control group (Con) consisting of healthy individuals matched for age, sex, and body mass index (n = 60). Following 24 weeks of Secukinumab treatment, significant reductions in PASI score, PGA, DLQI, Itch NRS, and STAI score were observed in psoriatic patients (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). The microbial diversity and composition in the AT group exhibited substantial alterations compared to the BT and Con groups, typified by an elevated abundance of\n                      <jats:italic toggle=\"yes\">Agathobacter<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">Anaerobutyricum<\/jats:italic>\n                      and a diminished presence of\n                      <jats:italic toggle=\"yes\">Bacteroides<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">Phocaeicola<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The changes in gut microbiota occur at a slower pace than cutaneous manifestations, necessitating prolonged follow-up and microbiome-based investigations in Secukinumab-treated psoriasis patients to substantiate its therapeutic efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_1025_24","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T05:00:08Z","timestamp":1759986008000},"page":"36-43","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Alterations of the Gut Microbiome in Psoriasis before and after Treated with Secukinumab"],"prefix":"10.4103","volume":"71","author":[{"given":"Ling","family":"Fang","sequence":"first","affiliation":[{"name":"From the Department of Dermatology, Xishan People\u2019s Hospital of Wuxi City, Wuxi Branch of Zhongda Hospital Southeast University, Wuxi, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Cheng","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Xishan People\u2019s Hospital of Wuxi City, Wuxi Branch of Zhongda Hospital Southeast University, Wuxi, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zuo","sequence":"additional","affiliation":[{"name":"YunLin Street Community Healthcare Center, Wuxi, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wuxi NO 2 People\u2019s Hospital, Central Hospital Affiliated to Jiangnan University, Wuxi, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"R1-20251231","doi-asserted-by":"crossref","first-page":"102916","DOI":"10.1016\/j.jaut.2022.102916","article-title":"Pathogenesis, multi-omics research, and clinical treatment of psoriasis","volume":"133","author":"Yu","year":"2022","journal-title":"J Autoimmun"},{"key":"R2-20251231","first-page":"111","article-title":"Non-randomized pilot study on the evaluation of the quality of life and psychosocial stress before and after systemic therapy in patients affected by moderate to severe psoriasis","volume":"23","author":"Panigalli","year":"2009","journal-title":"J Biol Regul Homeost Agents"},{"key":"R3-20251231","doi-asserted-by":"crossref","first-page":"e3263","DOI":"10.1002\/smi.3263","article-title":"Psychosocial stress affects the change of mental distress under dermatological treatment-A prospective cohort study in patients with psoriasis","volume":"40","author":"Wintermann","year":"2024","journal-title":"Stress Health"},{"key":"R4-20251231","first-page":"60","article-title":"Cosentyx (Secukinumab):First IL-17A Antagonist receives FDA approval for moderate-to-severe plaque psoriasis","volume":"9","author":"Fala","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"R5-20251231","doi-asserted-by":"crossref","first-page":"111065","DOI":"10.1016\/j.biopha.2020.111065","article-title":"Dysregulation of the gut-brain-skin axis and key overlapping inflammatory and immune mechanisms of psoriasis and depression","volume":"137","author":"Wang","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"R6-20251231","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.3390\/ijms24054568","article-title":"Compositional alteration of gut microbiota in psoriasis treated with IL-23 and IL-17 inhibitors","volume":"24","author":"Huang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R7-20251231","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s40261-019-00849-7","article-title":"Gut microbiome in psoriasis is perturbed differently during secukinumab and ustekinumab therapy and associated with response to treatment","volume":"39","author":"Yeh","year":"2019","journal-title":"Clin Drug Investig"},{"key":"R8-20251231","doi-asserted-by":"crossref","first-page":"adv00576","DOI":"10.2340\/00015555-3816","article-title":"Secukinumab exhibits sustained and stable response in patients with moderate-to-severe psoriasis:Results from the SUPREME study","volume":"101","author":"Costanzo","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"R9-20251231","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.2147\/CCID.S416149","article-title":"Long-term drug survival and effectiveness of secukinumab in patients with moderate to severe chronic plaque psoriasis:42-month results from the SUPREME 2.0 study","volume":"16","author":"Russo","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R10-20251231","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.19039","article-title":"British association of dermatologists guidelines for biologic therapy for psoriasis 2020:A rapid update","volume":"183","author":"Smith","year":"2020","journal-title":"Br J Dermatol"},{"key":"R11-20251231","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.rdc.2015.07.013","article-title":"Etiology and pathogenesis of psoriasis","volume":"41","author":"Boehncke","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"R12-20251231","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/09546634.2018.1528330","article-title":"Psoriasis-associated cutaneous pain:Etiology, assessment, impact, and management","volume":"30","author":"Pithadia","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"R13-20251231","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/09546634.2019.1572865","article-title":"Psoriasis-associated itch:Etiology, assessment, impact, and management","volume":"31","author":"Pithadia","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"R14-20251231","doi-asserted-by":"crossref","first-page":"17057","DOI":"10.1038\/nmicrobiol.2017.57","article-title":"Next-generation probiotics:The spectrum from probiotics to live biotherapeutics","volume":"2","author":"O'toole","year":"2017","journal-title":"Nat Microbiol"},{"key":"R15-20251231","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1007\/s13555-023-01007-w","article-title":"Causal associations between gut microbiota and psoriasis:A mendelian randomization study","volume":"13","author":"Zang","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R16-20251231","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s11427-018-9376-6","article-title":"Dysbiosis of gut microbiota was closely associated with psoriasis","volume":"62","author":"Huang","year":"2019","journal-title":"Sci China Life Sci"},{"key":"R17-20251231","doi-asserted-by":"crossref","first-page":"17292","DOI":"10.1038\/s41598-022-21708-0","article-title":"Profile of gut microbiota and serum metabolites associated with metabolic syndrome in a remote island most afflicted by obesity in Japan","volume":"12","author":"Uema","year":"2022","journal-title":"Sci Rep"},{"key":"R18-20251231","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2340\/00015555-1975","article-title":"Pruritus in psoriasis:A study of personality traits, depression and anxiety","volume":"95","author":"Remrod","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"R19-20251231","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1111\/1346-8138.16941","article-title":"Association of psoriasis with depression, anxiety, and suicidality:A bidirectional two-sample Mendelian randomization study","volume":"50","author":"Chu","year":"2023","journal-title":"J Dermatol"},{"issue":"Suppl 1","key":"R20-20251231","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000501991","article-title":"Secukinumab:The anti-IL-17A biologic for the treatment of psoriasis","volume":"11","author":"Fargnoli","year":"2019","journal-title":"Case Rep Dermatol"},{"key":"R21-20251231","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","article-title":"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis","volume":"144","author":"Krueger","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R22-20251231","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cyto.2017.05.018","article-title":"IL-17A causes depression-like symptoms via NFkappaB and p38MAPK signaling pathways in mice:Implications for psoriasis associated depression","volume":"97","author":"Nadeem","year":"2017","journal-title":"Cytokine"},{"key":"R23-20251231","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00284-022-03054-6","article-title":"Novel phocaeicola strain ameliorates dextran sulfate sodium-induced colitis in mice","volume":"79","author":"Sun","year":"2022","journal-title":"Curr Microbiol"},{"key":"R24-20251231","doi-asserted-by":"crossref","first-page":"1227309","DOI":"10.3389\/fmicb.2023.1227309","article-title":"Successful secukinumab therapy in plaque psoriasis is associated with altered gut microbiota and related functional changes","volume":"14","author":"Du","year":"2023","journal-title":"Front Microbiol"},{"key":"R25-20251231","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00253-022-11777-6","article-title":"Genetic tools for the redirection of the central carbon flow towards the production of lactate in the human gut bacterium Phocaeicola (Bacteroides) vulgatus","volume":"106","author":"Luck","year":"2022","journal-title":"Appl Microbiol Biotechnol"},{"key":"R26-20251231","doi-asserted-by":"crossref","first-page":"e0112421","DOI":"10.1128\/mra.01124-21","article-title":"Complete genome sequences of three phocaeicola vulgatus strains isolated from a healthy Japanese individual","volume":"11","author":"Vu","year":"2022","journal-title":"Microbiol Resour Announc"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_1025_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:00:18Z","timestamp":1786647618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_1025_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_1025_24","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"assertion":[{"value":"2024-12-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}